MindWalk Holdings (HYFT) Current Deferred Revenue (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Current Deferred Revenue of $782760.0 for Q2 2026, up 2.19% year-over-year from $765974.3 in Q2 2025, and up 15.44% quarter-over-quarter from $678056.1 in Q1 2026.
MindWalk Holdings (HYFT) Current Deferred Revenue (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Current Deferred Revenue for 7 consecutive years, with $782760.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Deferred Revenue rose 2.19% year-over-year to $782760.0; the TTM figure through Apr 2026 stood at $782760.0 (up 2.19% YoY), while the FY2026 annual figure was $782760.0, changed 0.03% from the prior year.
- Current Deferred Revenue advanced to $782760.0 in Q2 2026 per HYFT's latest filing, from $678056.1 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $1.7 million in Q1 2025 and bottomed at $565489.2 in Q3 2025.
- Historically, Current Deferred Revenue has averaged $929064.6 across 5 years, with a median of $830376.3 in 2022.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue jumped 148.27% — and 2026, when it sank 59.09%.
- MindWalk Holdings' Current Deferred Revenue stood at $885405.0 in 2022, then surged by 34.19% to $1.2 million in 2023, then rose by 5.83% to $1.3 million in 2024, then sank by 47.65% to $658162.5 in 2025, then gained by 18.93% to $782760.0 in 2026.
- Business Quant data shows HYFT's Current Deferred Revenue at $782760.0 in Q2 2026, $678056.1 in Q1 2026, and $658162.5 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 782,759.96 |
| Jan 31, 2026 | 678,056.09 |
| Oct 31, 2025 | 658,162.53 |
| Jul 31, 2025 | 565,489.20 |
| Apr 30, 2025 | 765,974.27 |
| Jan 31, 2025 | 1.66 Mn |
| Oct 31, 2024 | 1.26 Mn |
| Jul 31, 2024 | 950,135.88 |
| Apr 30, 2024 | 997,127.42 |
| Jan 31, 2024 | 1.50 Mn |
| Oct 31, 2023 | 1.19 Mn |
| Jul 31, 2023 | 844,352.69 |
| Apr 30, 2023 | 722,051.05 |
| Jan 31, 2023 | 602,753.66 |
| Oct 31, 2022 | 885,405.02 |
| Jul 31, 2022 | 1.08 Mn |
| Apr 30, 2022 | 816,400.01 |
| Jan 31, 2022 | 776,650.25 |
| Oct 31, 2021 | 1.03 Mn |
| Jul 31, 2021 | 1.02 Mn |